The unraveling of the human genome has created new avenues of discovery. Very important advances have been made in understanding how and when these genes are up or down regulated. Unfortunately the biological and biomedical role of the proteins encoded by many of these genes is still unknown. The understanding of the interactions among the many proteins holds the answers needed to better diagnose and treat disease.
Antibodies are key tools in effectively understanding the role of these genes and their proteins. The inherent sensitivity and specificity of the antibody allows the scientist to search for, identify, and study the proteins
they target.
Unfortunately, antibody development has lagged far behind human gene expression discovery. The availability of high quality, well characterized antibodies that can recognize human proteins in their native state is limited. Available antibodies are for the most part derived from peptide antigens making most of them western blot –grade (denatured epitope), but very few are capable of recognizing the protein in its native, clinically relevant state. Additionally available antibodies are for the most part polyclonal which makes standardization of assays and therapies derived from the use of this reagents practically impossible.
In response to the needs of the proteomic s field,CDI has
developed the Fast-MAb® antibody development platform,
which rapidly and efficiently generates MAbs that recognize
native human proteins with high affinity and unprecedented
specificity (High-Spec® Validation) which is conferred by
game-changing technology.